Clifford Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Clifford Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-115,237	Closed	-$2.48M	–	35
2018 Q3	$2.48M	Sell	115,237 -49,615	-30%	-$1.15M	2.35%	28
2018 Q2	$4.01M	Sell	164,852 -1,015	-0.6%	-$20.7K	4.17%	4
2018 Q1	$2.83M	Buy	165,867 +1,686	+1%	+$32.9K	2.99%	18
2017 Q4	$3.11M	Buy	+164,181	New	+$2.47M	3.45%	14

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Clifford Capital Partners's TEVA Position: Q4 2018 in Review

Clifford Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 115,237 shares — an estimated $2.48M sold.

Clifford Capital Partners first reported a position in TEVA in Q4 2017 and held it in 4 quarters. The position peaked at $4.01M in Q2 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Clifford Capital Partners reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Clifford Capital Partners sold 115,237 Teva Pharmaceuticals shares in Q4 2018, an estimated $2.48M.
Clifford Capital Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Clifford Capital Partners's Teva Pharmaceuticals position peaked at $4.01M in Q2 2018.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Clifford Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.